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ABSTRACT 
Four compounds, R3PAu[S2CN(CH2CH2OH)2], R = Ph (1) and Cy (2), and Et3PAuS2CNRꞌ2, Rꞌ = 
Rꞌ = Et (3) and Rꞌ2 = (CH2)4 (4), have been evaluated for antibacterial activity against a panel of 
24 Gram positive (8) and Gram negative (16) bacteria.  Based on minimum inhibitory 
concentration (MIC) scores, compounds 1 and 2 were shown to be specifically potent against Gram 
positive bacteria whereas compounds 3 and, to a lesser extent, 4 exhibited broad range activity.  
All four compounds were active against methicillin resistant Staphylococcus aureus (MRSA).  
Time kill assays revealed the compounds to exhibit both time- and concentration-dependent 
pharmacokinetics against susceptible bacteria.  Each compound was bactericidal against one or 
more bacteria with 3 being especially potent after 8 h exposure; compounds 1 and 3 were 
bactericidal against MRSA.  Compound 3 was the most effective bactericide across the series 
especially toward B. subtilis, S. saprophyticus, A. hydrophilia, P. vulgaris, and V. 
parahaemolyticus.  This study demonstrates the potential of this class of compounds as 
antibacterial agents, either broad range or against specific bacteria. 
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1. Introduction 
Global dissemination of antibacterial resistance has rendered worldwide health practice 
vulnerable [1].  Antibacterials are essential in the prevention and treatment of bacterial infection 
which commonly occurs in surgery, organ transplant, cancer chemotherapy, and in veterinary 
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applications [2].  In particular, the emergence of methicillin resistant Staphylococcus aureus 
(MRSA), vancomycin-resistant enterococci, third-generation cephalosporins resistant Escherichia 
coli and Klebsiella pneumonia, penicillin resistant Streptococcus pneumoniae, extended spectrum 
β-lactamase, and carbapenem-resistant Enterobacteriaceae are prominent examples that are both 
widespread and of great concern [3,4].  The emergence of bacterial resistance to drugs has called 
into question the effectiveness of current antibacterial chemotherapy.  The problem arises in part 
due to misuse of antimicrobial agents which have created environmental stress for bacteria 
promoting natural selection therefore contributing to resistance.  In order to survive bacteria 
promote resistance through genetic mutations and extrinsic acquaintance of resistance genes [5,6].  
Also of major concern over the past two decades is the relatively slow pace associated with the 
discovery of new classes of drugs and with the lack of exploitation of new generation drugs derived 
from existing licensed drugs [7].  A further challenge is that multidrug resistant bacteria are 
becoming ubiquitous in both developed and developing countries [8,9] and that newly discovered 
antibacterial agents have limited revolutionary mechanisms of action for clinical use [10].  These 
issues have motivated new strategies and initiatives launched by the Infectious Diseases Society 
of America (Policy), Action on Antibiotic Resistance (ReAct) [2,11], and The British Society for 
Antibiotic Chemotherapy (BSAC) [12] with the purpose of improving research and development 
of new antibacterial drugs. 
 
Metallopharmaceuticals relates to the use of metal based species in the treatment of various 
illnesses and highlights the importance of medicinal inorganic chemistry [13].  A prominent 
element in this context is gold [14-20].  While the clinical use of gold compounds for the treatment 
of rheumatoid arthritis and the development of both gold(I) and gold(III) compounds as anti-cancer 
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agents is well documented, their investigation as potential antimicrobial agents is emerging and 
has only recently been the subject of a comprehensive review [21].  Auranofin®, an orally 
administered disease modifying anti-rheumatic drug (DMARD), is a relatively late comer in the 
treatment of rheumatoid arthritis [14,15] but might be a good example of “drug 
repurposing/repositioning” whereby a clinically approved drug might find applications against 
other disease [22].  Indeed, auranofin® displays anticancer potential [23] and more recent studies 
indicate prospective antimicrobial applications [24].  The key structural feature of auranofin® is a 
linear P–Au–S geometry defined by phosphane and thiolate ligands [25].  The increasing interest 
in the antiproliferative activity of auranofin® builds upon investigations of a full range of gold(I) 
and gold(III) compounds [26-28], a good number of which contain the P–Au–S chromophore with 
thiolates such as mercaptopurinate [29-31], isomeric mercaptobenzoates [32,33], thiobenzoate [34] 
and, pertinent to the present investigation, 1,1-dithiolates such as dithiocarbamates and xanthates 
[35].  In keeping in with the wide range of biological activities exhibited by metal (incorporating 
transition and main group elements) dithiocarbamates [36], a relatively large number of studies 
have been conducted on phosphanegold(I) dithiocarbamates [37-41], including the determination 
of biological targets and mechanisms of cell death.  Given the emerging interest in the 
antimicrobial activity of gold compounds [36] and the knowledge that certain metal 
dithiocarbamates exhibit anti-microbial activity [21], recently a series of phosphanegold(I) 
dithiocarbamates, namely R3PAu[S2CN(iPr)CH2CH2OH] for R = Et, Cy and Ph, were investigated 
for antimicrobial activity against a panel of 25 strains of Gram-positive and Gram-negative 
bacteria [42].  While the R = Et compound had broad range activity against both Gram-positive 
and Gram-negative bacteria, the R = Cy and Ph compounds exhibited specific activity against 
Gram-positive bacteria.  Especially noteworthy was that the R = Et compound was potent toward 
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MRSA.  Time-kill studies indicated the R = Cy and Ph compounds were bactericidal whereas the 
R = Et compound was both bactericidal and bacteriostatic depending on the specific bacterial strain, 
observations suggesting different mechanisms of action are applicable depending on both the 
nature of the phosphane ligand and bacteria.  Given that earlier studies showed the Et3P ligand in 
gold compounds [43] and -S2CN(CH2CH2OH)2 ligands in copper and silver compounds [44] 
furnish active species, the foregoing studies were extended to the four compounds shown in Fig. 
1.  Herein, a study evaluating the potency of 1-4 against a panel of 24 Gram-positive and Gram-
negative clinical bacteria is reported.  The minimum inhibitory concentration (MIC) and minimum 
bactericidal concentration (MBC) have been determined as well as preliminary pharmacokinetics 
(time kill assays). 
 
 
2. Experimental 
2.1. Materials 
Reactions were carried out under ambient conditions; all chemicals and solvents were used 
as received.  The R3PAuCl precursors were synthesized by reducing HAuCl4 (Sigma-Aldrich) with 
sodium sulfite followed by addition of the respective phosphane ligand, i.e., Ph3P (Merck), Cy3P 
(Acros), and Et3P (Sigma-Aldrich).  The dithiocarbamate salts were prepared in quantitative yields 
from the reaction of the respective amine with KOH or NaOH and CS2, following literature 
precedents [45]; [NH4][S2CN(CH2)4] was purchased from Fisher. 
 
2.2. Instrumentation 
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Melting points were determined on a Mel-Temp II melting point apparatus.  Elemental 
analyses were performed on a Perkin Elmer PE 2400 CHN Elemental Analyser.  IR spectra were 
obtained by an Attenuated Total Reflectance (ATR) technique on a Perkin Elmer Spectrum 2000 
RX1 FTIR spectrophotometer; abbreviations: s = strong, m = medium, w = weak and sh = shoulder.  
1H and 13C{1H} NMR spectra were recorded in CDCl3 solution at 25 °C on JOEL LA and JOEL 
Lambda 400 MHz NMR spectrometers with chemical shifts referenced to the residual proton of 
CDCl3.  31P{1H} NMR spectra were recorded in CDCl3 solution at 25 °C on a Bruker Avance 400 
MHz NMR spectrometer with the chemical shifts recorded relative to 85% aqueous H3PO4 as 
external reference; abbreviations for NMR assignments: s, singlet; d, doublet; t, triplet; q, 
quartet;  m, multiplet. 
 
2.3 Synthesis and characterization 
2.3.1 Triphenylphosphanegold(I) (N,N-dihydroxyethyldithiocarbamate) (1) 
K[S2CN(CH2CH2OH)2] (0.20 g, 1 mmol) in water (30 ml) was added dropwise to a 
suspension of Ph3PAuCl (0.49 g, 1 mmol) in acetone (5 ml).  The solution was stirred for 1 h to 
give a yellow gum.  Water was decanted and after several washings with water, the gum was 
dissolved in a minimum volume of methanol and this was added dropwise into diethylether (1 l) 
while stirring vigorously until precipitation occurred.  The yellow precipitates were separated 
using a separating funnel.  The yellow precipitate that deposited at the bottom of the separating 
funnel was isolated and allowed to dry at room temperature.  Yield: 66%.  M.Pt: 150.0 °C.  1H 
NMR: δ 7.45-7.58 (15H, m, aryl-H); 4.22 (4H, t, NCH2, J = 6 Hz); 4.10 (4H, t, CH2O, J = 6 Hz) 
ppm; OH not observed.  13C{1H} NMR: δ 209.9 (CS); 128.5-134.2 (aryl-C); 61.2 (CH2O); 59.5 
(NCH2) ppm.  31P{1H} NMR: δ 34.56 ppm.  IR (cm-1): 1436 (sh, m) v(C–N); 1027 (w), 997 (sh, 
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m) v(C‒S).  Anal. Calc. for C23H25AuNO2PS2: C, 41.25; H, 3.46; N, 2.29%.  Found: C, 41.65; H, 
3.65; N, 2.01%. 
2.3.1 Tricyclohexylphosphanegold(I) (N,N-dihydroxyethyldithiocarbamate) (2) 
Compound 2 was prepared as for 1 but using Cy3PAuCl as the precursor.  Yield: 67%.  M.Pt: 
162.5 °C.  1H NMR: δ 4.20 (4H, t, NCH2, J = 6 Hz); 4.08 (4H, t, OCH2, J = 6 Hz); 3.37 (2H, s, 
OH); 1.26-2.02 (33H, m, Cy-H) ppm.  13C{1H} NMR: δ 210.5 (CS); 61.3 (CH2O); 59.1 (NCH2); 
33.4 (CHP); 30.6 (CH2CHP); 27.1 (CH2CH2CHP); 26.0 (CH2CH2CH2CHP) ppm.  31P{1H} NMR: 
δ 55.42 ppm.  IR (cm-1): 1458 (m) ν(C–N); 1065 (s), 985 (sh, m) ν(C‒S).  Anal. Calc. for 
C23H43AuNO2PS2: C, 40.06; H, 6.24; N, 2.22%.  Found: C, 40.46; H, 6.64; N, 2.62%. 
 
2.3.3 Triethylphosphanegold(I) (N,N-diethyldithiocarbamate) (3) 
Na[S2CNEt2] (0.14 g, 1mmol) was dissolved in water (20 ml) and added dropwise to a 
suspension of Et3PAuCl (035 g, 1 mmol) in acetone (10 ml).  The solution was stirred for 1 h after 
which a bright-yellow gum was obtained.  Solvent extraction with chloroform/water (3:1) followed.  
The chloroform layer was filtered off, dried over Na2SO4, and allowed to dry at room temperature 
to yield a yellow crystals [35].  Yield: 80%.  M.Pt: 91.2 °C.  31P{1H} NMR: δ 33.99 ppm.  IR (cm-
1): 1484 (sh, s) ν(C–N); 1047 (sh, s), 982 (sh, s) ν(C‒S).  Anal. Calc. for C11H25AuNPS2: C, 28.51; 
H, 5.44; N, 3.02%.  Found: 28.91; H, 5.10; N, 3.42%. 
 
2.3.4 Triethylphosphanegold(I) (N,N-pyrrolidinedithiocarbamate) (4) 
Compound 4 was prepared and recrystallized as for 3 but using NH4[S2CN(CH2)4].  Yield: 
895%.  M.Pt: 76.2 °C.  1H NMR: δ 3.76 (4H, t, NCH2, J = 8 Hz); 1.93 (4H, t, NCH2CH2, J = 8 
Hz); 1.77 (6H, dq, PCH2, J = 8, 4 Hz); 1.17 (9H, dt, PCH2CH3, J = 8, 4 Hz) ppm.  13C{1H} NMR: 
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δ 202.1 (CS); 53.5 (NCH2); 25.6 (NCH2CH2); 17.8 (PCH2); 8.5 (PCCH3) ppm.  31P{1H} NMR: δ 
34.31 ppm.  IR (cm-1): 1432 (s, m) ν(C–N); 1040 (s, sh), 999 (s, sh) ν(C‒S).  Anal. Calc. for 
C11H23AuNPS2: C, 28.64; H, 5.02; N, 3.04%. Found: 29.04; H, 5.06; N, 2.93%. 
 
2.4 Anti-bacterial activity studies 
2.4.1 Preparation of Test Organism 
A total of 24 clinically important pathogens were used in this study and these were purchased from 
American Type Culture Collection (ATCC).  This included eight Gram-positive and 16 Gram-
negative bacteria.  The bacteria were Enterococcus faecalis (ATCC 29212), Enterococcus faecium 
(ATCC 19434), Bacillus cereus (ATCC 10876), Bacillus subtilis (ATCC 6633), Staphylococcus 
aureus (ATCC 25923), Staphylococcus aureus MRSA (ATCC 43300), Staphylococcus 
saprophyticus (ATCC 15305), Listeria monocytogenes (ATCC 19117), Enterobacter cloacae 
(ATCC 35030), Enterobacteraerogenes (ATCC 13048), Salmonella typhimurium (ATCC 14028), 
Salmonella paratyhi A (ATCC 9150), Shigellasonnei (ATCC 9290), Shigellaflexneri (ATCC 
12022), Pseudomonas aeruginosa (ATCC 27853), Klebsiellapneumoniae (ATCC 700603), Vibrio 
parahaemolyticus (ATCC 17802), Proteus mirabilis (ATCC 25933), Acinetobacterbaumannii 
(ATCC 19606), Proteus vulgaris (ATCC 13315), Stenotrophomonasmaltophilia (ATCC 13637), 
Citrobacterfreundii (ATCC 8090), Escherichia coli (ATCC 25922), and 
Aeromonashydrophila(ATCC 35654).  Colonies of each bacterial strain were picked from cultures 
grown on agar plates and inoculated into Mueller-Hinton broth (MHB) (Difco) to prepare the 
inoculum suspension. 
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2.4.2 Disk Diffusion 
A concentration of 2 mg/ml of each test compound was used in this study using DMSO as the 
solvent.  According to the Clinical and Laboratory Standards Institute (CLSI) guidelines, bacterial 
suspensions with density corresponding to a McFarland 0.5 turbidity standard, which corresponds 
to 108 CFU/ml, was swabbed onto Mueller-Hinton agar (MHA) (Difco) with a sterile cotton swab.  
Six sterile filter paper discs of 6 mm were applied on each MHA and an anti-biotic treated disc, 
the positive control, was placed in the center of the agar.  For each test compound, 5 µl solution 
was dropped on the filter paper disc.  Similar volumes of MHB, which served as the negative 
control, and DMSO (Merck), as the solvent control, were also dropped on another two blank discs.  
Each plate was then incubated for 24 h at 37 ºC or 30 ºC incubators depending on the optimum 
growth conditions of each bacterium.  Each determination was performed in triplicate.  The 
diameter of the inhibition zone produced by each bacterial strain representing antibacterial activity 
was measured in millimeter and interpreted with CLSI standard interpretative criteria (CLSI, 2012). 
 
2.4.3 MIC and MBC determination 
The broth micro-dilution method was used to define the potency of the test compounds by 
determining the lowest concentration required to hinder bacterial growth (minimum inhibitory 
concentration, MIC) or to completely kill the bacterium (minimum bactericidal concentration, 
MBC).  MIC determination was performed in accordance with the recommended CLSI protocols.  
Test compounds were prepared by two-fold serial dilutions to achieve final concentrations ranging 
from 100 to 0.003 µg/ml.  Each test compound (5µl) was then added into wells of 96-well 
microplates containing 105 CFU/ml of exponentially growing bacterial cells.  Controls were also 
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included in each microplate comprising DMSO (solvent control), MHB (negative control), 
standard antibiotics, i.e., tetracycline or chloramphenicol (positive control), and bacterial cells only.  
The microplates were subsequently incubated for 24 h at 37 ºC or 30 ºC.  Each test was performed 
in triplicate.  As an indicator of bacterial growth, 50 µl of 0.2 mg/ml p-iodonitrotetrazolium violet 
(Sigma-Aldrich) was added into each well and the microplates were further incubated for at least 
30 mins under aerobic agitation.  The presence of bacterial activity converts the dye from colorless 
to purple.  The MIC was determined as the lowest concentration at which there was no trace of 
purple.  After MIC determination, the MBC was determined by subculture of 100 µl aliquots from 
each well with no visible growth on MHA followed by incubating overnight at 37 ºC.  MBC 
endpoint was defined as the lowest concentration of the compounds that kills more than 99.9% of 
bacteria which is taken to represent no bacterial growth on agar. 
 
2.4.4. Time-kill assay 
Further to the evaluation of antibacterial activity, a time kill assay was performed with macro-
dilution according to the method recommended by CLSI.  Bacterial cells in the exponential growth 
phase were cultured and diluted to approximately 105 CFU/ml.  Solutions (100 µl) of test 
compounds with concentrations corresponding to ½ MIC, MIC and 2 MIC were added into the 
inoculum suspension.  MHB inoculated with each bacterial strain without test compound acted as 
the control in this experiment.  The inoculum cultures were incubated at 37 ºC on an orbital shaker 
at 200 rpm.  Samples (200 µl) were removed from each inoculum culture at time points 0, 1, 2, 3, 
4, 8, and 24 h, ten-fold serially diluted in 0.9 % normal saline and 25 µl subcultured from each 
dilution on MHA.  Viable counts were calculated in the units of cfu/ml and kill curves were plotted 
with time (h) against logarithm of the viable count (log10 CFU).  Each experiment was carried out 
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in triplicate and analyzed with mean variables.  Bactericidal effects of a compound were seen when 
≥ 3 log10 decrease in viable colony relative to initial inoculum [46]. 
 
 
3. Results and discussion 
3.1 Chemistry 
Four phosphanegold(I) dithiocarbamate compounds, 1-4, have been prepared for 
antimicrobial assays in the present study, Fig. 1.  While 1 and 2, with hydroxyethyl functionalized 
dithiocarbamate ligands and 4 are new, 3 is a known compound [35] and the crystal structure of 3 
is available [47].  A number of studies are now available suggesting that dithiocarbamate ligands 
with hydroxyethyl groups possess biological activity [43,44,48,49] and therefore it was thought of 
interest to extend the studies to 1 and 2, given the anti-bacterial activity of 
R3PAu[S2CN(iPr)CH2CH2OH] for R = Et, Cy and Ph [42].  Compounds 3 and 4 were included in 
the present study as they contain Et3P, as in Auranofin®, and have conventional dithiocarbamate 
ligands which have demonstrated biological activity when complexed to metals [36].  The 
spectroscopic characteristics are as expected and confirm the anticipated compositions, Fig. 1.  
While crystal structures were not obtained for 1, 2, or 4, despite best efforts, it is expected based 
on literature precedents of mononuclear phosphanegold(I) dithiocarbamates [39,41,47,50-56], that 
each of 1, 2, and 4 feature a linear P–Au–S geometry arising from an essentially monodentate 
mode of coordination of the dithiocarbamate ligand.  Finally, the stability of 1-4 in d6-DMSO 
solution was monitored by 1H over a week.  No discernible changes were noted in any of the 
spectra suggesting the compounds remain intact over the time-scale of the biological assays. 
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3.2 Antibacterial activity 
The in vitro effects of 1-4 on 8 Gram-positive and 16 Gram-negative pathogens were 
evaluated using the disk diffusion method with results summarized in Table 1.  
The -S2CN(CH2CH2OH)2 anion, as in 1 and 2, showed no activity against any of the bacteria.  
Similarly the -S2CNEt2 anion showed poor activity, having effects on two Gram positive bacteria 
only and no effect on Gram negative bacteria.  By contrast, the -S2CN(CH2)4 anion proved mildly 
active to all but two of the Gram positive bacteria and to five of the Gram negative bacteria 
evaluated.  Attention is next turned to the phosphanegold(I) compounds of these anions. 
 
Despite having no activity itself, when the -S2CN(CH2CH2OH)2 anion is complexed as in 1 
and 2, specific but modest activity is seen toward Gram positive bacteria, with 1 tending to be 
marginally more potent than 2.  The trend toward greater potency upon complexation of the 
dithiocarbamate ligands is also evident for 3 and 4 but, unlike 1 and 2, 3 and 4 display broad range 
activity.  For 3, significantly enhanced activity against all Gram positive bacteria cf. the free anion 
was observed.  Against Gram negative pathogens 3 proved active against all the bacteria.  
Generally 3 proved more potent against Gram positive bacteria being most active against S. 
saprophyticus (29 mm) and least against E. faecium (20 mm) whereas against Gram negative 
bacteria, greatest activity was noted against S. flexneri (17 mm) and least against K. pneumonia 
and P. aeruginosa (8 mm). 
 
For 4, significantly enhanced activity against all Gram positive bacteria, cf. the free anion, 
was also noted.  Compound 4 proved active against all the Gram negative bacteria susceptible to 
the free anion but was more potent against all except against C. freundii, i.e., 17 cf. 9 mm for the 
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anion and 4, respectively.  This being stated, differences in potency between the free anion and 4 
were generally small except against C. freundii, i.e., 9 cf. 26 mm, respectively.  Compound 4 also 
showed activity against five Gram negative bacteria not susceptible to the anion.  Potency was 
greater against Gram positive bacteria, e.g., S. saprophyticus (30 mm) and E. faecium (21 mm), 
mirroring the trend for 3.  With the exception of S. aureus, i.e., 26 and 24 mm, respectively, 4 was 
consistently more potent than 3 although differences are small.  While 4 was also active against 
10 Gram negative bacteria, the potency was the same (P. vulgaris) or reduced cf. 3.  Finally, while 
3 and 4 displayed a broader spectrum of activity, the observation of their reduced potency against 
Gram negative bacteria is probably related to the presence of the outer wall membrane which 
functions as an additional protective layer that restricts the influx of the trial compounds [57,58]. 
 
3.3 Determination of minimum inhibitory concentration and minimum bactericidal 
concentration 
Having established zones of inhibition, Table 1, attention was next directed toward 
ascertaining the minimum inhibitory concentration (MIC) of the anions and 1-4 against susceptible 
strains; data are summarized in Table 2.  MIC values for the -S2CNEt2 anion were >100 mg/ml or 
not determinable indicating no antibacterial activity.  For the -S2CN(CH2)4 anion, smaller values 
were observed with 3.125 (C. freundii), 6.25 (B. cereus), and all remaining susceptible strains 
having MIC >12.5.  Significantly lower MIC values were observed for 1-4, again consistent with 
the pivotal role of the phosphanegold(I) entity in generating antibacterial agents. 
For 1, MIC values ranged from 0.39 µg/ml (B. cereus) to 6.25 mg/ml (E. faecalis) and for 2, 
from 1.56 mg/ml (B. cereus and L. monocytogenes) to 50.00 µg/ml (S. aureus), suggesting the 
greater efficacy of the Ph3P phosphane ligand over Cy3P in these compounds.  As a general trend, 
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the MIC values against each Gram positive bacterium effected by 3 and 4 were considerably lower 
than for effected by 1 and 2.  With the exception of MIC values for L. monocytogenes (0.20 µg/ml) 
and each of E. faecalis and E. faecium (0.39 µg/ml), 3 induced MIC values of 0.10 µg/ml in the 
remaining Gram-positive bacteria.  A wider range of MIC values were evident for 4, ranging from 
a low 0.05 µg/ml against B. subtilis to 0.39 µg/ml against E. faecium.  Differences between 3 and 
4 were seen against B. subtilis (0.10 vs. 0.05 µg/ml) and E. faecalis (0.39 vs. 0.20 µg/ml).  More 
variety was noted when Gram negative bacteria were subjected to 3 and 4.  Against S. sonnei, the 
MIC for 3 was greater than that for 4 (3.13 vs 1.56 µg/ml), the values were the same against each 
of A. baumannii, P. vulgaris, and V. parahaemolyticus, and were reduced against the remaining 
pathogens, Table 2.  From the foregoing, a general trend may be seen whereby 4 is slightly more 
active than 3 against Gram positive bacteria but, 3 exhibits broad range activity against Gram 
negative bacteria. 
 
Given that inhibition of bacterial growth does not necessarily imply a trial compound can 
kill a particular bacterium [59], the minimum bactericidal concentration (MBC) was determined 
in order to identify whether the trial compound was able to kill the bacterium (bactericidal) or 
simply inhibited growth (bacteriostatic).  In light of the increasing bacterial resistance to Gram 
positive antibiotics, the development of bactericides is a priority over inhibition and subsequent 
regrowth [60].  The definition of MBC by Levison [61] is employed herein.  A compound is 
considered a bactericidal agent if the MBC value is ≤ 4 x MIC.  Conversely, a compound is 
bacteriostatic if the MBC > 4 x MIC. From the data collated in Table 2, it is evident that 1 is 
bactericidal against all Gram positive bacteria with the exception of E. faecium.  Compound 2 is 
also bacteriostatic toward E. faecium as well as to S. saprophyticus, being bactericidal to the 
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remaining six bacteria, notably MRSA.  Quite distinctive behaviour differentiates 3 and 4.  Against 
Gram positive bacteria, 3 is bactericidal against all but E. faecium.  By contrast, 4 is bactericidal 
toward L. monocytogenes, S. aureus, and S. saprophyticus only.  Against Gram negative bacteria, 
3 is generally bactericidal, killing all tested bacteria except K. pneumonia, P. aeruginosa, and S. 
maltophilia.  Finally, 4 was bactericidal against five Gram negative bacteria, namely A. 
hydrophilla, S. flexneri, S. sonnei, P. vulgaris, and V. parahaemolyticus. 
 
In summary, 3 exhibits broad range antibacterial activity toward both Gram positive and 
Gram negative bacteria and is generally bactericidal. 
 
3.4 Time kill assay 
Apart from MBC determination a time kill based approach is a useful model to describe the 
pharmacodynamics of a trial compound [62].  By contrast to MIC determination, which 
investigates the antimicrobial effect at one concentration after a specific time, the time kill assay 
involves evaluating the effect of different concentrations, i.e., 2 x, 1 x, and 0.5 x MIC, over 24 h 
incubation.  Following CLSI protocols, a 3 log10CFU/ml or greater reduction in the viability of the 
bacterial colony is the point of differentiation between bactericidal and bacteriostatic activity 
(lower values). 
 
The time-kill curves for 1 and 2 are shown in Figs. 2 and 3, respectively, and data are given 
in Table 3.  At doses of the 1 x MIC value, 1 was bactericidal toward B. cereus (-5.1 log10 CFU/ml) 
after 1 h, and after 2 h toward B. subtilis (-3.3 log10 CFU/ml) being bacteriostatic against the other 
bacteria.  Differential 1 x MIC behavior was observed for 2 as this was bactericidal after 1 h 
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application in B. subtilis (-5.1 log10 CFU/ml) and MRSA (-5.4 log10 CFU/ml), and after 2 h in E. 
faecalis (-3.3 log10 CFU/ml).  At 2 x MIC 1 was bactericidal toward B. cereus (-5.1 log10 CFU/ml) 
and B. subtilis (-3.1 log10 CFU/ml) after 1 h, and after 4h MRSA (-5.4 log10 CFU/ml).  Under the 
same conditions, 2 exhibited bactericidal effects after 1 h toward B. cereus (-5.1 log10 CFU/ml), B. 
subtilis (-5.1 log10 CFU/ml), MRSA (-5.4 log10 CFU/ml), and S. saprophyticus (-4.9 log10 CFU/ml); 
2 h: E. faecalis (-5.7 log10 CFU/ml), and 8 h: S. aureus (-4.6 log10 CFU/ml).  At ½ x MIC, 1 was 
uniformly bacteriostatic but 2 was bactericidal against both B. subtilis (-5.1 log10 CFU/ml) and 
MRSA (-5.4 log10 CFU/ml) after 1 h administration. 
 
The time kill curves for 3 and 4 are shown in Figs. 4 and 5, respectively, and data are given 
in Table 4.  In the timeframe of the experiments and at 2 x MIC, 3 was bactericidal against all 
bacteria with the notable exceptions of E. faecium, K. pneumonia, P. aeruginosa, and S. 
maltophilia.  As a general observation, bactericidal effects were noted only after 8 h administration 
in most bacteria; 3 h for E. coli and 4 h for A. baumannii.  The remaining bacteria were killed by 
3 after 1 h: B. subtilis (-5.1 log10 CFU/ml), S. saprophyticus (-5.0 log10 CFU/ml), A. hydrophilia 
(-5.8 log10 CFU/ml), P. vulgaris (-6.0 log10 CFU/ml), and V. parahaemolyticus (-5.6 log10 CFU/ml).  
One of these, i.e., P. vulgaris, was also susceptible at ½ x MIC after 1 h while at this dose B. 
subtilis and V. parahaemolyticus were killed after 2 h, and 4 h was required for S. saprophyticus; 
at ½ x MIC 3, was bacteriostatic toward A. hydrophilia. 
Consistent with the MBC results, 4 was bacteriostatic against most of the bacteria.  The most 
promising activity was seen against S. saprophyticus (-5.0 log10 CFU/ml) but at 2 x MIC after 8 h 
exposure. 
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From the foregoing, it is evident that a greater killing rate was observed in susceptible 
bacteria with the egress of time.  Also, a concentration dependence was seen.  Detectable regrowth 
of bacteria was noted for 1 and 2 but, generally not for bacteria treated with 3 and 4, behavior that 
may be correlated with selective development of resistant- and killing-susceptible subpopulations 
[46,63]. 
 
4. Conclusions 
Phosphanegold(I) dithiocarbamate compounds 1-4 and literature precedents [42] offer 
prospects as antimicrobial agents displaying time- and concentration-dependent bactericidal 
activity against a range of Gram positive and Gram negative bacteria.  In terms of a structure 
activity relationship based on the present and literature study [42], i) species with hydroxyethyl-
substituted dithiocarbamate ligands are generally less promising than their all alkyl counterparts, 
and ii) compounds with triethylphosphane ligands are more potent than phenyl and cyclohexyl 
analogues.  The most promising compound of the present series, 3, had equal to (one example) or 
lower MIC values than standard antibiotics and were bactericidal against Gram positive bacteria.  
While the standard antibiotics often had lower MIC values against Gram negative bacteria, 3, by 
contrast to the standards, was generally bactericidal offering potential as a novel therapeutic agent 
for the treatment of a wide range of bacterial infections.  In summary, the new results reported 
herein coupled with recently discoveries of other gold compounds of other thiolates [64], 
sulfanylcarboxylates [65], and carbenes [66] indicates further research investigating the 
antibacterial activity of gold compounds is warranted. 
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Table 1 
Anti-bacterial activity measured by zone of inhibition (mm) of dithiocarbamate anions, 1–4, and standard anti-biotics.a,b 
Microorganism 
 
-S2CNR12 1 2 -S2CNR22 3 -S2CNR3 4 Tetracycline 
(30 µg/disc) 
Chloramphenicol 
(30 µg/disc) 
Gram-positive bacteria 
   B. cereus ATCC 10876 
 
– 
 
8 
 
7 
 
7 
 
22 
 
12 
 
24 
 
17 
 
ND 
   B. subtilis ATCC 6633 
– 
10 8 11 27 17 29 31 ND 
   E. faecalis ATCC 29212 
– 
7 8 - 22 13 23 14 ND 
   E. faecium ATCC 19434 
– 
8 8 - 20 - 21 ND 22 
   L. monocytogenes ATCC 19117 
– 
9 8 - 24 13 24 27 ND 
   S. aureus (MRSA) ATCC 43300 
– 
10 8 - 27 14 28 ND 20 
   S. aureus ATCC 25923 
– 
10 8 - 26 16 24 ND 18 
   S. saprophyticus ATCC 15305 
– 
10 8 - 29 13 30 30 ND 
Gram-negative bacteria 
   A. baumannii ATCC 19606 
 
– 
 
– 
 
– 
 
- 
 
14 
 
- 
 
12 
 
20 
 
ND 
   A. hydrophilla ATCC35654 
– – – 
- 14 10 12 27 ND 
25 
 
   C. freundii ATCC 8090 
– – – 
- 11 17 9 26 ND 
   E. aerogenes ATCC 13048 
– – – 
- 13 - - 22 ND 
   E. cloacae ATCC 35030 
– – – 
- 11 - - 22 ND 
   E. coli ATCC 25922 
– – – 
- 12 - 8 24 ND 
   K. pneumonia ATCC 700603 
– – – 
- 8 - - 15 ND 
   P. aeruginosa ATCC 27853 
– – – 
- 8 - - 10 ND 
   S. typhimurium ATCC 14028 
– – – 
- 12 - 10 22 ND 
   S. paratyphi A ATCC 9150 
– – – 
- 12 - 9 27 ND 
   S. flexneri ATCC 12022 
– – – 
- 17 14 15 26 ND 
   S. sonnei ATCC 9290 
– – – 
- 13 - 10 26 ND 
   S. maltophilia ATCC 13637 
– – – 
- 11 - – ND 25 
   P. mirabilis ATCC25933 
– – – 
- 10 - 9 ND 19 
   P. vulgaris ATCC 13315 
– – – 
- 13 9 13 ND 20 
   V. parahaemolyticus ATCC17802 
– – – 
- 15 10 14 24 ND 
a
 The diameter of inhibition zones in millimetres were measured around the disc after 24 h incubation; –, no zone of inhibition; 
ND, not determined.  b R1 = CH2CH2OH, R2 = ethyl, and R3  
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Table 2 
MIC (in microgram per milliliter) and MBC (in microgram per milliliter) dithiocarbamate anions, 1–4, and standard anti-biotics against 
susceptible Gram-positive and Gram-negative bacteria.a 
 
 
Microorganism 
1 2 -S2CNR22 
 
3 
 
-S2CNR3 
 
4 
 
Standard anti-
biotics 
 
MIC 
 
MBC/
MIC 
 
MIC 
 
MBC/
MIC 
 
MIC 
 
MBC/
MIC 
 
MIC 
 
MBC/
MIC 
 
MIC 
 
MBC/
MIC 
 
MIC 
 
MBC/
MIC 
 
MIC 
 
MBC/
MIC 
Gram-positive bacteria 
   B. cereus ATCC 10876 
 
0.39 
 
1 
 
1.56 
 
2 
 
100.00 
 
ND 
 
0.10 
 
1 
 
6.25 
 
>16 
 
0.10 
 
>1024 
 
6.25c 
 
1 
   B. subtilis ATCC 6633 0.78 1 25.00 1 100.00 ND 0.10 1 12.50 >8 0.05 >2048 0.10c 1 
   E. faecalis ATCC 29212 6.25 1 12.50 1 - - 0.39 1 25.00 1 0.20 >512 12.50c 1 
   E. faecium ATCC 19434 3.13 16 6.25 16 - - 0.39 8 - - 0.39 >256 12.50d ND 
   L. monocytogenes ATCC 19117 1.56 1 1.56 1 - - 0.20 1 12.50 >8 020 1 12.50c 1 
   S. aureus (MRSA) ATCC 43300 1.56 1 6.25 2 - - 0.10 1 25.00 ND 0.10 512 12.50d 1 
   S. aureus ATCC 25923 1.56 1 50.00 1 - - 0.10 1 12.50 1 0.10 1 12.50d 1 
   S. saprophyticus ATCC 15305 1.56 1 3.13 8 - - 0.10 2 12.50 >8 0.10 4 0.39c ND 
Gram-negative bacteria 
   A. baumannii ATCC 19606 - - - - - - 
 
1.56 
 
1 
 
- 
 
- 
 
1.56 
 
>64 
 
0.39c 
 
32 
   A. hydrophilla ATCC 35654 
- - - - - - 0.78 1 50.00 ND 3.13 2 0.39c 1 
   C. freundii ATCC 8090 
- - - - - - 6.25 4 3.125 >32 25.00 >4 0.78c 32 
   E. aerogenes ATCC 13048 
- - - - - - 1.56 2 - - - - 1.56c 32 
   E. cloacae ATCC 35030 
- - - - - - 6.25 2 - - - - 1.56c ND 
   E. coli ATCC 25922 
- - - - - - 3.13 2 - - 12.50 8 0.39c ND 
   K. pneumonia ATCC 700603 
- - - - - - 6.25 8 - - - - 12.50c ND 
27 
 
   P. aeruginosa ATCC 27853 
- - - - - - 12.50 >8 - - - - 6.25c ND 
   S. typhimurium ATCC 14028  
- - - - - - 3.13 2 - - 6.25 >16 1.56c 32 
   S. paratyphi A ATCC 9150 
- - - - - - 1.56 1 - - 12.50 8 1.56c 32 
   S. flexneri ATCC 12022 
- - - - - - 1.56 2 12.50 >8 3.13 4 0.78c 32 
   S. sonnei ATCC 9290 - - - - - - 3.13 2 - - 1.56 2 0.78c 32 
   S. maltophilia ATCC 13637 
- - - - - - 1.56 8 - - - - 3.13d ND 
   P. mirabilis ATCC25933 
- - - - - - 6.25 2 - - - - 12.50d 8 
   P. vulgaris ATCC 13315 
- - - - - - 3.13 2 50.00 ND 3.13 4 12.50d 4 
   V. parahaemolyticus ATCC 17802 - - - - - - 0.39 2 25.00 ND 0.39 1 0.10c 1 
a
 MIC minimum inhibitory concentration (µg/ml), MBC minimum bactericidal concentration (µg/ml), MBC/MIC ratio for bacteriostatic 
or bactericidal activity, – not applicable, ND, not determined as the bacterium had grown across all tested dilutions (MBC > 2000 µg/ml), 
MBC/MIC > 4 showed bacteriostatic properties.  b R1 = CH2CH2OH, R2 = ethyl, and R3 = (CH2)4.  c tetracycline.  d chloramphenicol. 
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Table 3 
Summary of in vitro time-kill assay of 1 and 2 against susceptible pathogen strains. 
 
Microorganism 
 
Compound 
  Δlog10 cfu/ml a  
½ x MIC  MIC 2 x MIC 
1h 2h 3h 4h 8h 24h  1h 2h 3h 4h 8h 24h  1h 2h 3h 4h 8h 24h 
B. cereus ATCC 10876 1 
2 
+0.7 
+0.1 
+1.5 
+0.7 
+2.8 
+1.8 
+3.1 
+2.8 
+3.9 
+3.5 
+4.9 
+3.0 
-5.1 
-2.3 
-1.6 
-2.0 
-1.1 
-1.3 
-0.9 
-0.1 
+3.1 
+2.9 
+4.3 
+2.8 
-5.1 
-5.1 
-5.1 
-5.1 
-5.1 
-5.1 
-2.5 
-5.1 
+1.6 
-5.1 
+4.0 
+2.8 
B. subtilis ATCC 6633 1 
2 
-0.3 
-5.1 
-0.1 
-5.1 
+0.5 
-5.1 
+1.1 
-5.1 
+3.1 
-5.1 
+3.2 
+0.3 
-2.0 
-5.1 
-3.3 
-5.1 
-5.1 
-5.1 
-2.2 
-5.1 
+0.9 
-5.1 
+2.9 
-0.2 
-5.1 
-5.1 
-5.1 
-5.1 
-5.1 
-5.1 
-2.6 
-5.1 
+0.6 
-5.1 
+2.9 
-1.2 
E. faecalis ATCC 29212 1 
2 
+0.1 
-0.1 
+0.1 
-2.3 
+0.2 
-2.0 
0.0 
-1.8 
-0.4 
-1.3 
+5.9 
+6.0 
0.0 
-0.3 
-0.1 
-3.3 
-0.2 
-5.7 
-0.4 
-5.7 
-1.9 
-5.7 
+1.4 
-5.7 
0.0 
-1.8 
0.4 
-5.7 
-0.5 
-5.7 
-1.6 
-5.7 
-3.1 
-5.7 
-2.6 
-5.7 
E. faecium ATCC 19434 1 
2 
0.0 
+0.2 
+0.6 
+0.8 
+1.7 
+0.7 
+3.0 
+4.3 
+5.8 
+3.2 
+6.0 
+3.9 
-0.2 
-0.2 
+0.4 
0.0 
+0.7 
-0.1 
+2.5 
+0.5 
+5.7 
+1.3 
+5.9 
+2.9 
-0.2 
-0.1 
+0.2 
-0.2 
+0.2 
0.1 
+0.3 
+0.2 
+0.9 
+2.8 
+5.9 
+2.9 
L. monocytogenes ATCC 19117 1 
2 
+0.1 
-0.2 
+0.1 
-0.1 
+0.9 
+0.5 
+1.8 
+0.8 
+4.8 
+2.0 
+5.2 
+5.0 
-0.1 
-0.1 
-0.1 
-0.1 
-0.1 
+0.1 
-0.4 
+0.5 
+4.1 
+1.9 
+5.1 
+4.9 
-0.2 
-0.1 
-0.2 
-0.2 
-0.1 
-0.3 
-0.3 
-0.2 
-0.3 
-0.8 
+5.1 
+4.9 
S. aureus (MRSA) ATCC 43300 1 
2 
+0.4 
-5.4 
+0.2 
-5.4 
+0.1 
-5.4 
+0.1 
-5.4 
-0.3 
-5.4 
+6.2 
-0.6 
-0.4 
-5.4 
-0.6 
-5.4 
-1.0 
-5.4 
-1.2 
-5.4 
-2.7 
-5.4 
+2.9 
-5.4 
-0.4 
-5.4 
-1.0 
-5.4 
-1.5 
-5.4 
-2.4 
-5.4 
-5.4 
-5.4 
-5.4 
-5.4 
S. aureus ATCC 25923 1 
2 
+0.2 
-0.1 
+0.5 
+0.2 
+1.5 
+0.5 
+1.7 
+1.2 
+6.5 
+3.3 
+6.9 
+5.8 
-0.2 
-0.2 
+0.1 
-0.2 
+0.1 
-0.3 
-0.2 
-0.5 
-0.4 
-0.5 
+3.6 
+5.7 
-0.3 
-0.2 
-0.2 
-0.2 
-0.3 
-0.4 
-0.4 
-0.8 
-1.5 
-4.6 
+1.6 
+0.6 
S. saprophyticus ATCC 15305 1 
2 
+0.2 
+0.2 
+0.3 
+0.4 
+1.0 
+1.1 
+1.1 
+1.4 
+6.5 
+5.9 
+6.6 
+6.7 
-0.1 
-0.0 
-0.1 
-0.3 
-0.3 
+0.1 
-0.3 
+0.1 
-0.8 
+1.8 
+6.6 
+6.6 
-0.4 
-4.9 
-0.6 
-4.9 
-0.6 
-4.9 
-0.6 
-4.9 
+0.3 
-4.9 
+6.4 
+6.5 
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a Relative to log10 cfu/ml of initial inoculum (a negative value indicates a reduction of bacterial cell number, and a positive value indicates 
an increase of bacterial cell number).  Values shown are the means of triplicate determinations from each experiment. 
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Table 4 
Summary of in vitro time-kill assay of 3 and 4 against susceptible pathogen strains. 
 
Microorganism 
 
Compound 
Δlog10 cfu/ml a 
½ x MIC   MIC  2 x MIC 
1h 2h 3h 4h 8h 24h  1h 2h 3h 4h 8h 24h  1h 2h 3h 4h 8h 24h 
Gram-positive bacteria                    
B. cereus ATCC 10876 3 
4 
+0.1 
-0.1 
-0.1 
+0.1 
-0.1 
+0.1 
-0.1 
+0.1 
-0.2 
0.0 
+3.0 
+2.8 
+0.1 
-0.3 
-0.2 
-0.3 
-0.3 
-0.3 
-0.4 
-0.2 
-0.9 
-0.3 
-2.2 
-1.7 
-0.6 
-0.7 
-0.4 
-0.2 
-1.1 
-0.2 
-1.3 
-0.2 
-5.2 
-0.5 
-5.2 
-2.2 
B. subtilis ATCC 6633 3 
4 
-1.5 
+0.1 
-5.1 
-0.1 
-5.1 
-0.3 
-5.1 
-0.1 
-5.1 
+2.7 
-5.1 
+3.1 
-5.1 
-0.1 
-5.1 
-1.4 
-5.1 
-0.3 
-5.1 
-0.3 
-5.1 
-0.8 
-5.1 
+2.8 
-5.1 
-0.1 
-5.1 
-0.2 
-5.1 
-0.4 
-5.1 
-0.4 
-5.1 
-1.0 
-5.1 
-1.6 
E. faecalis ATCC 29212 3 
4 
0.0  
+0.2 
+0.1 
+0.1 
0.0 
-0.1 
0.0 
-0.1 
0.0 
-0.1 
-1.9 
+0.4 
0.0 
+0.1 
+0.1 
0.0 
0.0 
-0.1 
0.0 
-0.2 
-0.1 
-0.2 
-5.8 
0.0 
-0.1 
0.0 
-0.2 
-0.1 
-0.1 
-0.2 
-0.1 
-0.2 
-0.1 
-0.3 
-5.8 
-0.1 
E. faecium ATCC 19434 3 
4 
-0.1 
0.0 
0.0 
-0.1 
-0.1 
0.0 
-0.1 
+0.3 
+0.2 
+0.3 
+1.2 
0.0 
0.0 
-0.1 
0.0 
-0.1 
0.0 
0.0 
-0.2 
+0.1 
0.0 
-0.1 
+0.3 
0.0 
-0.3 
-0.1 
+0.1 
-0.1 
-0.1 
-0.1 
-0.2 
0.0 
+0.2 
+0.1 
-0.2 
0.0 
L. monocytogenes ATCC 19117 3 
4 
-0.1 
-0.1 
+0.2 
+0.1 
+0.1 
-0.1 
-0.1 
+0.1 
-0.4 
-0.3 
-1.5 
+0.8 
-0.1 
-0.1 
0.0 
-0.2 
-0.1 
-0.1 
-0.1 
-0.1 
-0.4 
-0.4 
-6.4 
-2.7 
-0.1 
0.0 
-0.1 
-0.4 
-0.1 
-0.1 
-0.3 
-0.1 
-0.8 
-1.2 
-6.4 
-2.7 
S. aureus (MRSA) ATCC 43300 3 
4 
0.0 
+0.2 
0.0 
+0.1 
+0.1 
+0.2 
-0.1 
+0.1 
-0.2 
+0.1 
-1.0 
+5.8 
-0.1 
+0.1 
-0.4 
0.0 
-0.5 
+0.1 
-0.7 
+0.1 
-1.9 
0.0 
-5.7 
-0.3 
-0.3 
-0.2 
-0.8 
0.0 
-1.8 
0.0 
-2.1 
0.0 
-4.1 
-0.4 
-5.7 
-0.8 
S. aureus ATCC 25923 3 
4 
+0.1 
0.0 
0.0 
-0.1 
-0.1 
0.0 
0.0 
0.0 
-0.1 
0.0 
-0.5 
+0.5 
+0.1 
0.0 
0.0 
0.0 
-0.1 
0.0 
-0.1 
-0.1 
-0.9 
0.0 
-5.2 
+0.3 
0.0 
0.0 
-0.4 
-0.1 
-0.4 
-0.2 
-1.2 
-0.8 
-5.2 
-2.0 
-5.2 
-5.2 
S. saprophyticus ATCC 15305 3 
4 
0.0 
+0.3 
-0.8 
+0.4 
-2.1 
+0.2 
-5.0 
+0.2 
-5.0 
+0.4 
-5.0 
+3.6 
-0.7 
-0.1 
-5.0 
-0.1 
-5.0 
0.0 
-5.0 
0.0 
-5.0 
-0.6 
-5.0 
+1.2 
-5.0 
-0.1 
-5.0 
-0.4 
-5.0 
-0.8 
-5.0 
-1.8 
-5.0 
-5.0 
-5.0 
-5.0 
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Gram-negative bacteria 
A. baumannii ATCC 19606 
 
 
3 
4 
 
 
-0.1 
+0.4 
 
 
-0.1 
+1.3 
 
 
-0.2 
+5.2 
 
 
-0.3 
+5.2 
 
 
-1.7  
+5.5 
 
 
+0.4 
+5.6 
  
 
+0.1 
+0.1 
 
 
-0.3 
+1.1 
 
 
-0.4 
3.9 
 
 
-1.0 
+5.0 
 
 
-6.0 
+4.9 
 
 
-6.0 
+5.6 
 
 
 
 
-0.2 
-0.1 
 
 
-0.6 
+0.7 
 
 
-1.3 
+2.7 
 
 
-6.0 
+3.9 
 
 
-6.0 
+4.5 
 
 
-6.0 
+5.5 
A. hydrophilla ATCC 35654 3 
4 
+0.1 
0.0 
+0.1 
0.0 
+0.2 
0.0 
+0.3 
+0.1 
+0.3 
+1.9 
+5.1 
+3.4 
 -0.7 
0.0 
-2.8 
-0.1 
-2.8 
-0.3 
-4.1 
-0.1 
-5.8 
-0.6 
-5.8 
+3.6 
 -5.8 
-0.1 
-5.8 
-0.1 
-5.8 
-0.3 
-5.8 
-0.4 
-5.8 
-0.6 
-5.8 
0.0 
C. freundii ATCC 8090 3 
4 
+0.1 
+0.1 
+0.1 
+0.0 
+0.0 
+0.1 
-0.2 
+0.6 
-1.3 
+0.8 
-3.2 
+2.9 
 -0.2 
0.0 
-0.9 
0.0 
-1.2 
+0.1 
-1.9 
+0.1 
-3.6 
+0.1 
-6.0 
+2.5 
 -0.6 
-0.1 
-2.0 
0.0 
-3.5 
0.0 
-4.0 
0.0 
-6.0 
0.0 
-6.0 
-0.3 
E. aerogenes ATCC 13048 3 +0.1 +0.2 +0.2 +0.3 +4.9 +9.7  +0.1 +0.1 -0.1 -0.5 -1.2 -3.3  +0.1 -0.7 -0.9 -1.6 -5.8 -5.8 
E. cloacae ATCC 35030 3 0.0 -0.3 -0.2 -0.4 -3.4 -6.1  -0.1 -0.4 -1.3 -2.0 -6.0 -6.1  -0.2 -1.0 -2.4 -4.6 -6.0 -6.1 
E. coli ATCC 25922 3 
4 
+0.2 
+0.3 
-0.4 
+0.3 
-1.5 
+0.7 
-1.7 
+0.9 
-3.1 
+0.2 
+3.4 
+3.2 
 -0.3 
+0.1 
-1.3 
0.0 
-3.5 
+0.3 
-5.4 
+0.3 
-5.4 
0.0 
-5.4 
+3.0 
 -0.5 
0.0 
-2.5 
-0.2 
-5.4 
+0.1 
-5.4 
+0.1 
-5.4 
0.0 
-5.4 
+0.1 
K. pneumonia ATCC 700603 3 +0.2 +1.7 +3.1 +6.4 +7.3 +7.6  0.0 -0.1 -0.4 -0.3 -1.2 +3.1  +0.1 -0.1 -0.3 -0.3 -2.1 -0.5 
P. aeruginosa ATCC 27853 3 0.0 +0.7 +1.9 +2.0 +3.8 +4.0  -0.1 +0.1 +0.3 +1.0 +3.2 +3.8  -0.2 0.0 +0.1 +0.2 +3.0 +3.1 
S. typhimurium ATCC 14028 3 
4 
0.0 
-0.2 
+0.1 
-0.2 
-0.2 
-0.2 
-0.1 
-0.3 
-2.1 
-0.3 
+1.5 
+2.9 
 -0.1 
-0.2 
-0.3 
-0.3 
-0.4 
-0.2 
-1.0 
-0.3 
-3.2 
-0.7 
-5.9 
+2.4 
 -0.1 
-0.1 
-0.4 
-0.2 
-1.0 
-0.2 
-1.5 
-0.3 
-5.9 
-0.8 
-5.9 
+0.7 
S. paratyphi A ATCC 9150 3 
4 
+0.1 
-0.2 
+0.6 
-0.4 
+1.3 
-0.2 
+2.0 
-0.3 
+2.9 
-0.6 
+3.1 
-1.2 
 +0.2 
-0.4 
-0.8 
-0.3 
-1.4 
-0.2 
-2.1 
-0.4 
-1.9 
-0.8 
+3.1 
-1.7 
 -0.8 
-0.4 
-2.7 
-0.4 
-3.4 
-0.4 
-4.2 
-0.4 
-5.8 
-0.7 
-5.8 
-2.1 
S. flexneri ATCC 12022 3 
4 
0.0 
+0.3 
+0.1 
-0.1 
0.0 
-0.1 
0.0 
-0.4 
-0.2 
-0.7 
-2.9 
+2.7 
 0.0 
-0.1 
-0.2 
-0.1 
-0.3 
-0.4 
0.0 
-0.4 
-0.4 
-0.9 
-5.9 
+2.4 
 0.0 
0.0 
-0.1 
-0.1 
-0.3 
-0.4 
-0.1 
-0.7 
-1.1 
-0.9 
-5.9 
-5.9 
S. sonnei ATCC 9290 3 
4 
0.0 
-0.1 
+0.2 
0.0 
0.0 
-0.3 
-0.1 
-0.8 
-0.2 
-1.1 
-2.8 
-0.1 
 0.0 
-0.2 
-0.1 
-0.1 
0.0 
-0.5 
-0.1 
-0.9 
-0.9 
-1.1 
-5.8 
-2.3 
 +0.1 
-0.1 
-0.1 
-0.3 
-0.1 
-0.8 
-0.7 
-0.9 
-1.8 
-1.6 
-5.8 
-3.1 
S. maltophilia ATCC 13637 3 0.0 +0.5 +0.8 +0.8 +3.7 +5.0  -0.1 +0.1 +0.1 +0.3 +1.1 +3.2  -0.2 -0.1 -0.3 -0.3 -1.0 +2.2 
P. mirabilis ATCC 25933 3 0.0 -0.1 -0.3 -0.5 -2.3 +5.2  -0.1 -0.3 -0.4 -0.5 -4.8 -6.1  -0.1 -0.2 -0.5 -1.2 -6.0 -6.1 
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P. vulgaris ATCC 13315 3 
4 
-6.0 
-0.1 
-6.0 
-1.2 
-6.0 
-3.5 
-6.0 
-6.0 
-6.0 
-6.0 
-6.0 
-6.0 
 -6.0 
-0.2 
-6.0 
-1.6 
-6.0 
-6.0 
-6.0 
-6.0 
-6.0 
-6.0 
-6.0 
-6.0 
 -6.0 
-0.4 
-6.0 
-1.8 
-6.0 
-6.0 
-6.0 
-6.0 
-6.0 
-6.0 
-6.0 
-6.0 
V. parahaemolyticus ATCC 17802 3 
4 
-2.0 
+0.2 
-5.6 
+0.2 
-5.6 
-0.5 
-5.6 
-0.5 
-5.6 
-0.7 
-5.6 
+2.6 
 -5.6 
-0.2 
-5.6 
-0.4 
-5.6 
-0.4 
-5.6 
-0.5 
-5.6 
-1.1 
-5.6 
+2.2 
 -5.6 
-0.6 
-5.6 
-1.7 
-5.6 
-2.7 
-5.6 
-3.7 
-5.6 
-5.6 
-5.6 
-5.6 
a Relative to log10 cfu/ml of initial inoculum (a negative value indicates a reduction of bacterial cell number, and a positive value indicates 
an increase of bacterial cell numbers).  Values shown are the means of triplicate determinations from each experiment. 
 
Captions to Figures 
 
Fig. 1.  Chemical diagrams of the investigated phosphanegold(I) dithiocarbamates. 
 
Fig 2.  Time kill curves of 1 against (a) B. cereus, (b) B. subtilis, (c) E. faecalis, (d) E. faecium, (e) 
L. monocytogenes, (f) S. aureus (MRSA), (g) S. aureus, and (h) S. saprophyticus.  The bactericidal 
level is indicated by the dashed lines , negative control , ½ MIC , MIC , and 2 x 
MIC . 
 
Fig 3.  Time kill curves of 2 against (a) B. cereus, (b) B. subtilis, (c) E. faecalis, (d) E. faecium, (e) 
L. monocytogenes, (f) S. aureus (MRSA), (g) S. aureus, and (h) S. saprophyticus.  The bactericidal 
level is indicated by the dashed lines , negative control , ½ MIC , MIC  , and2x 
MIC . 
 
Fig 4.  Time kill curves of 3 against (a) B. cereus, (b) B. subtilis, (c) E. faecalis, (d) E. faecium, (e) 
L. monocytogenes, (f) S. aureus (MRSA), (g) S. aureus, (h) S. saprophyticus, (i) A. baumannii, (j) 
A. hydrophila, (k) C. freundii, (l) E. aerogenes, (m) E. Cloacae, (n) E. coli, (o) K. pneumonia, (p) 
P. aeruginosa, (q) S. typhimurium, (r) S. paratyphi A (s) S. flexneri, (t) S. sonnei, (u) S. maltophilia, 
(v) P. mirabilis, (w) P. vulgaris, and (x) V. parahaemolyticus.  The bactericidal level is indicated 
by the dashed lines , negative control , ½ MIC , MIC , and 2 x MIC . 
 
Fig 5.  Time kill curves of 4 against (a) B. cereus, (b) B. subtilis, (c) E. faecalis, (d) E. faecium, (e) 
L. monocytogenes, (f) S. aureus (MRSA), (g) S. aureus, (h) S. saprophyticus, (i) A. baumannii, (j) 
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A. hydrophila, (k) C. freundii, (l) E. coli, (m) S. typhimurium, (n) S. paratyphi A, (o) S. flexneri, 
(p) S. sonnei, (q) P. vulgaris, and (r) V. parahaemolyticus.  The bactericidal level is indicated by 
the dashed lines , negative control , ½ MIC , MIC , and 2 x MIC . 
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